Read E.V.I.dently Today for current news about health policy and events, among other topics.
E.V.I.dently Today Blog
NPC Board Chair and BMS SVP Michael Ryan reflects on the biopharmaceutical industry's role in solving global health challenges and how to address misunderstandings about what it takes to bring innovative medicines to market.
Thanks to a recent IRS rule, high-deductible health plans with health savings accounts can now cover an expanded list of preventive services and medications before patients meet their plan’s annual out-of-pocket deductible. While still early in the adoption, this policy change — and others — can help remove disincentives for patients to receive high-value care.
In his editorial in the American Journal of Managed Care®, NPC Interim President and CEO Robert Dubois, PhD, MD, says we need to address social determinants of health (SDOH) and improve patients’ lives through approaches based on strong data. Given the clear association between SDOH and health outcomes, “building the evidence base for SDOH must be job one. Good policy can only be led by good data.”
Health care policy experts gathered for a panel discussion at the AcademyHealth 2021 Datapalooza and National Health Policy Conference in February to discuss key questions regarding government funding for research, vaccine pricing, incentives and innovation. The panel session, “If the NIH Funds the Research, Should There Be a 'Government Discount?” was moderated by National Pharmaceutical Council (NPC) Interim President and CEO Robert Dubois, and featured Northwestern University’s Craig Garthwaite, Brigham and Women's Hospital’s Aaron Kesselheim, University of Minnesota’s Stephen Parente, and the Milken Institute’s Kristin Schneeman.
A study by the National Pharmaceutical Council and the Research Triangle Institute Health Solutions provides guidance on quality metrics and practices that can help decision makers understand which budget cap features have the potential to lessen the impact on patient health and offers recommendations that could reduce any damage.
Roughly 30 million people in the United States are living with a rare disorder, facing challenges such as affordable and timely access to therapies, provider networks, coverage, care coordination and clinical expertise. Last fall, stakeholders met virtually for an Academy of Managed Care Pharmacy Partnership Forum to discuss viable solutions to these challenges.